Search Results for "ATTR-CM"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B

Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US

Explore ATTR-CM

Click the link above to access a resource that explores the pathophysiology, disease burden, recognition, and diagnosis of ATTR-CM.

Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan

Gene Silencing Therapeutics in Cardiology: A Review Article

Evaluation of Disease Progression in Patients with ATTR Amyloidosis with Cardiomyopathy Following Treatment with Patisiran: Post hoc Analysis of the APOLLO-B Study

Exploratory Biomarker Analyses from HELIOS-B, A Phase 3 Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

APOLLO-B, a Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis: Primary Long-term Results from the Open-label Extension Period

Exploratory Analyses from APOLLO-B, A Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Effects of Vutrisiran on Echocardiographic Cardiac Structure and Function: The HELIOS-B Trial

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.